# Niclosamide in COVID-19

> **NCT04542434** · PHASE2 · WITHDRAWN · sponsor: **Entero Therapeutics**

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Niclosamide Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04542434
- **Lead sponsor:** Entero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-20
- **Primary completion:** 2022-01-20
- **Final completion:** 2022-01-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor asset acquired by another pharma company who opened their own IND for this compound. First Wave Bio never started this study in the US or ex-US.
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542434, "Niclosamide in COVID-19". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04542434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*